Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 07:58 ET | Source: Research and Markets

Nasal Allergy Treatment Analysis, Growth Trends and Forecast 2025-2032: Market Remains Fragmented as Key Players Drive Growth Through Innovation and Regulatory Approvals

Dublin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The "Nasal Allergy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application,...
July 15, 2025 05:26 ET | Source: Research and Markets

Chronic Rhinosinusitis with Nasal Polyps Market Analysis and Forecast Report 2025-2035, Featuring AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, Sanofi, and More

Dublin, July 15, 2025 (GLOBE NEWSWIRE) -- The "Chronic Rhinosinusitis with Nasal Polyps Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast,...
September 10, 2020 18:00 ET | Source: Lyra Therapeutics

Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis

Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
September 03, 2020 16:05 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis

WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
August 05, 2020 16:05 ET | Source: Lyra Therapeutics

Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
August 04, 2020 16:05 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference

WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
August 04, 2020 08:00 ET | Source: Lyra Therapeutics

Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs

WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
July 30, 2020 16:05 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference

WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
July 24, 2020 08:30 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update

WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
July 07, 2020 08:30 ET | Source: Lyra Therapeutics

Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development

WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...